nach oben

Cancer and Metastasis Reviews

Erschienen in:

03.09.2019

The role of proteases in epithelial-to-mesenchymal cell transitions in cancer

verfasst von: Julia Mitschke, Ulrike C. Burk, Thomas Reinheckel

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Changing the characteristics of cells from epithelial states to mesenchymal properties is a key process involved in developmental and physiological processes as well as in many diseases with cancer as the most prominent example. Nowadays, a great deal of work and literature concerns the understanding of the process of epithelial-to-mesenchymal transition (EMT) in terms of its molecular regulation and its implications for cancer. Similar statements can certainly be made regarding the investigation of the more than 500 proteases typically encoded by a mammalian genome. Specifically, the impact of proteases on tumor biology has been a long-standing topic of interest. However, although EMT actively regulates expression of many proteases and proteolytic enzymes are clearly involved in survival, division, differentiation, and movements of cells, information on the diverse roles of proteases in EMT has been rarely compiled. Here we aim to conceptually connect the scientific areas of “EMT” and “protease” research by describing how several important classes of proteolytic enzymes are regulated by EMT and how they are involved in initiation and execution of the EMT program. To do so, we briefly introduce the evolving key features of EMT and its regulation followed by discussion of protease involvement in this process.

Greenburg, G., & Hay, E. D. (1982). Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. Journal of Cell Biology, 95(1), 333–339. https://doi.org/10.1083/jcb.95.1.333.CrossRefPubMed

Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871–890. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

Ahmed, N., Maines-Bandiera, S., Quinn, M. A., Unger, W. G., Dedhar, S., & Auersperg, N. (2006). Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. American Journal of Physiology-Cell Physiology, 290(6), C1532–C1542. https://doi.org/10.1152/ajpcell.00478.2005.CrossRefPubMed

Arnoux, V., Nassour, M., L’Helgoualc’h, A., Hipskind, R. A., & Savagner, P. (2008). Erk5 controls slug expression and keratinocyte activation during wound healing. Molecular Biology of the Cell, 19(11), 4738–4749. https://doi.org/10.1091/mbc.e07-10-1078.CrossRefPubMedPubMedCentral

Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H., & Neilson, E. G. (2002). Evidence that fibroblasts derive from epithelium during tissue fibrosis. The Journal of Clinical Investigation, 110(3), 341–350. https://doi.org/10.1172/JCI15518.CrossRefPubMedPubMedCentral

Stone, R. C., Pastar, I., Ojeh, N., Chen, V., Liu, S., Garzon, K. I., & Tomic-Canic, M. (2016). Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell and Tissue Research. NIH Public Access. https://doi.org/10.1007/s00441-016-2464-0.PubMedPubMedCentralCrossRef

Grande, M. T., Sánchez-Laorden, B., López-Blau, C., De Frutos, C. A., Boutet, A., Arévalo, M., … Nieto, M. A. (2015). Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nature Medicine, 21(9), 989–997. doi:https://doi.org/10.1038/nm.3901.PubMedCrossRef

Peinado, H., Olmeda, D., & Cano, A. (2007, March). Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Reviews. Cancer. https://doi.org/10.1038/nrc2131.PubMedCrossRef

Shin, S., Dimitri, C. A., Yoon, S. O., Dowdle, W., & Blenis, J. (2010). ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Molecular Cell, 38(1), 114–127. https://doi.org/10.1016/j.molcel.2010.02.020.CrossRefPubMedPubMedCentral

10.

Janda, E., Lehmann, K., Killisch, I., Jechlinger, M., Herzig, M., Downward, J., … Grünert, S. (2002). Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis. The Journal of Cell Biology, 156(2), 299–314. doi:https://doi.org/10.1083/jcb.200109037.PubMedPubMedCentralCrossRef

11.

Puisieux, A., Brabletz, T., & Caramel, J. (2014). Oncogenic roles of EMT-inducing transcription factors. Nature Cell Biology. https://doi.org/10.1038/ncb2976.PubMedCrossRef

12.

Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019). Non-redundant functions of EMT transcription factors. Nature Cell Biology. https://doi.org/10.1038/s41556-018-0196-y.PubMedCrossRef

13.

Savagner, P., Yamada, K. M., & Thiery, J. P. (1997). The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor–induced epithelial–mesenchymal transition. The Journal of Cell Biology, 137(6), 1403–1419. https://doi.org/10.1083/JCB.137.6.1403.CrossRefPubMedPubMedCentral

14.

Vandewalle, C., Comijn, J., De Craene, B., Vermassen, P., Bruyneel, E., Andersen, H., … Berx, G. (2005). SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Research, 33(20), 6566–78. doi:https://doi.org/10.1093/nar/gki965.PubMedPubMedCentralCrossRef

15.

Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., … Eger, A. (2007). The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene, 26(49), 6979–6988. doi:https://doi.org/10.1038/sj.onc.1210508.PubMedPubMedCentralCrossRef

16.

Spaderna, S., Schmalhofer, O., Wahlbuhl, M., Dimmler, A., Bauer, K., Sultan, A., … Brabletz, T. (2008). The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Research, 68(2), 537–544. doi:https://doi.org/10.1158/0008-5472.CAN-07-5682.PubMedCrossRef

17.

Yilmaz, M., & Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews, 28(1–2), 15–33. https://doi.org/10.1007/s10555-008-9169-0.CrossRefPubMed

18.

Miyoshi, A., Kitajima, Y., Sumi, K., Sato, K., Hagiwara, A., Koga, Y., & Miyazaki, K. (2004). Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. British Journal of Cancer, 90(6), 1265–1273. https://doi.org/10.1038/sj.bjc.6601685.CrossRefPubMedPubMedCentral

19.

Jordà, M., Olmeda, D., Vinyals, A., Valero, E., Cubillo, E., Llorens, A., … Fabra, A. (2005). Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the snail transcription factor. Journal of Cell Science, 118(Pt 15), 3371–85. doi:https://doi.org/10.1242/jcs.02465.PubMedCrossRef

20.

Hu, F., Wang, C., Guo, S., Sun, W., Mi, D., Gao, Y., … Yang, S. (2011). δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1809(3), 200–210. doi:https://doi.org/10.1016/J.BBAGRM.2011.01.003.CrossRef

21.

Sanchez-Tillo, E., de Barrios, O., Siles, L., Cuatrecasas, M., Castells, A., & Postigo, A. (2011). Catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proceedings of the National Academy of Sciences, 108(48), 19204–19209. https://doi.org/10.1073/pnas.1108977108.CrossRef

22.

Wu, W.-S., You, R.-I., Cheng, C.-C., Lee, M.-C., Lin, T.-Y., & Hu, C.-T. (2017). Snail collaborates with EGR-1 and SP-1 to directly activate transcription of MMP 9 and ZEB1. Scientific Reports, 7(1), 17753. https://doi.org/10.1038/s41598-017-18101-7.CrossRefPubMedPubMedCentral

23.

Drak Alsibai, K., & Meseure, D. (2018). Tumor microenvironment and noncoding RNAs as co-drivers of epithelial–mesenchymal transition and cancer metastasis. Developmental Dynamics. John Wiley & Sons, Ltd. doi:https://doi.org/10.1002/dvdy.24548.PubMedCrossRef

24.

Korpal, M., Ell, B. J., Buffa, F. M., Ibrahim, T., Blanco, M. A., Celià-Terrassa, T., … Kang, Y. (2011). Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine, 17(9), 1101–1109. doi:https://doi.org/10.1038/nm.2401.PubMedPubMedCentralCrossRef

25.

Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275–292. https://doi.org/10.1016/j.cell.2011.09.024.CrossRefPubMedPubMedCentral

26.

Brabletz, T. (2012). To differentiate or not—routes towards metastasis. Nature Reviews Cancer, 12(6), 425–436. https://doi.org/10.1038/nrc3265.CrossRefPubMed

27.

Polyak, K., & Weinberg, R. A. (2009, April). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews. Cancer. https://doi.org/10.1038/nrc2620.PubMedCrossRef

28.

Marusyk, A., & Polyak, K. (2010). Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta, 1805(1), 105–117. https://doi.org/10.1016/j.bbcan.2009.11.002.CrossRefPubMed

29.

Meacham, C. E., & Morrison, S. J. (2013). Tumor heterogeneity and cancer cell plasticity. Nature, 501(7467), 328. https://doi.org/10.1038/NATURE12624.CrossRefPubMedPubMedCentral

30.

Grosse-Wilde, A., Fouquier d’Hérouël, A., McIntosh, E., Ertaylan, G., Skupin, A., Kuestner, R. E., … Huang, S. (2015). Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One, 10(5), e0126522. doi:https://doi.org/10.1371/journal.pone.0126522.PubMedPubMedCentralCrossRef

31.

Jolly, M. K., Tripathi, S. C., Jia, D., Mooney, S. M., Celiktas, M., Hanash, S. M., … Levine, H. (2016). Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget, 7(19), 27067–27084. https://doi.org/10.18632/oncotarget.8166.

32.

Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., … Blanpain, C. (2018). Identification of the tumour transition states occurring during EMT. Nature, 556(7702), 463–468. doi:https://doi.org/10.1038/s41586-018-0040-3.PubMedCrossRef

33.

Kröger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., … Weinberg, R. A. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proceedings of the National Academy of Sciences, 201812876. doi:https://doi.org/10.1073/pnas.1812876116.CrossRef

34.

Wiedow, O., & Meyer-Hoffert, U. (2005). Neutrophil serine proteases: Potential key regulators of cell signalling during inflammation. Journal of Internal Medicine. John Wiley & Sons, ltd (10.1111). https://doi.org/10.1111/j.1365-2796.2005.01476.x.PubMedCrossRef

35.

Turk, B., Turk, D., & Turk, V. (2012). Protease signalling: the cutting edge. The EMBO Journal, 31(7), 1630–1643. https://doi.org/10.1038/emboj.2012.42.CrossRefPubMedPubMedCentral

36.

Pišlar, A., Perišić Nanut, M., & Kos, J. (2015). Lysosomal cysteine peptidases – molecules signaling tumor cell death and survival. Seminars in Cancer Biology, 35, 168–179. https://doi.org/10.1016/J.SEMCANCER.2015.08.001.CrossRefPubMed

37.

Zhao, P., Metcalf, M., & Bunnett, N. W. (2014). Biased signaling of protease-activated receptors. Frontiers in Endocrinology, 5, 67. https://doi.org/10.3389/fendo.2014.00067.CrossRefPubMedPubMedCentral

38.

Winer, A., Adams, S., & Mignatti, P. (2018). Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Molecular Cancer Therapeutics, 17(6), 1147–1155. https://doi.org/10.1158/1535-7163.MCT-17-0646.CrossRefPubMedPubMedCentral

39.

Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (New York, N.Y.), 295(5564), 2387–2392. https://doi.org/10.1126/science.1067100.CrossRef

40.

Löser, R., & Pietzsch, J. (2015). Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes. Frontiers in Chemistry, 3, 37. https://doi.org/10.3389/fchem.2015.00037.CrossRefPubMedPubMedCentral

41.

Vandooren, J., Opdenakker, G., Loadman, P. M., & Edwards, D. R. (2016). Proteases in cancer drug delivery. Advanced Drug Delivery Reviews, 97, 144–155. https://doi.org/10.1016/j.addr.2015.12.020.CrossRefPubMed

42.

Vidak, E., Javoršek, U., Vizovišek, M., & Turk, B. (2019). Cysteine Cathepsins and their extracellular roles: shaping the microenvironment. Cells, 8(3), 264. https://doi.org/10.3390/cells8030264.CrossRefPubMedCentral

43.

Weidle, U. H., Tiefenthaler, G., & Georges, G. (2014). Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genomics and Proteomics, 11(2), 67-79.

44.

Sloane, B. F., List, K., Fingleton, B., & Matrisian, L. (2013). Proteases in cancer: significance for invasion and metastasis. In Proteases: structure and function (pp. 491–550). Vienna: Springer Vienna. https://doi.org/10.1007/978-3-7091-0885-7_15.CrossRef

45.

Sevenich, L., & Joyce, J. A. (2014). Pericellular proteolysis in cancer. Genes & Development, 28(21), 2331–2347. https://doi.org/10.1101/gad.250647.114.CrossRef

46.

Olson, O. C., & Joyce, J. A. (2015). Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nature Reviews Cancer, 15(12), 712–729. https://doi.org/10.1038/nrc4027.CrossRefPubMed

47.

Mohamed, M. M., & Sloane, B. F. (2006). Multifunctional enzymes in cancer. Nature Reviews Cancer, 6(10), 764–775. https://doi.org/10.1038/nrc1949.CrossRefPubMed

48.

Anja, P., Anahid, J., & Janko, K. (2018). Cysteine cathepsins: their biological and molecular significance in cancer stem cells. Seminars in Cancer Biology, 53, 168–177. https://doi.org/10.1016/J.SEMCANCER.2018.07.010.CrossRef

49.

Eatemadi, A., Aiyelabegan, H. T., Negahdari, B., Mazlomi, M. A., Daraee, H., Daraee, N., … Sadroddiny, E. (2017). Role of protease and protease inhibitors in cancer pathogenesis and treatment. doi:https://doi.org/10.1016/j.biopha.2016.12.021.CrossRef

50.

Friedl, P., & Wolf, K. (2010). Plasticity of cell migration: a multiscale tuning model. The Journal of Cell Biology, 188(1), 11–19. https://doi.org/10.1083/jcb.200909003.CrossRefPubMedPubMedCentral

51.

Friedl, P., & Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell Cell Press. https://doi.org/10.1016/j.cell.2011.11.016.CrossRefPubMed

52.

Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/10.1016/j.cell.2010.03.015.CrossRefPubMedPubMedCentral

53.

Duffy, M. J., McKiernan, E., O’Donovan, N., & McGowan, P. M. (2009). Role of ADAMs in cancer formation and progression. Clinical Cancer Research, 15(4), 1140–1144. https://doi.org/10.1158/1078-0432.CCR-08-1585.CrossRefPubMed

54.

Tanabe, L. M., & List, K. (2017). The role of type II transmembrane serine protease-mediated signaling in cancer. The FEBS Journal, 284(10), 1421–1436. https://doi.org/10.1111/febs.13971.CrossRefPubMed

55.

Noë, V., Fingleton, B., Jacobs, K., Crawford, H. C., Vermeulen, S., Steelant, W., … Mareel, M. (2001). Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. Journal of Cell Science, 114(Pt 1), 111–118.

56.

Deryugina, E. I., Ratnikov, B., Monosov, E., Postnova, T. I., DiScipio, R., Smith, J. W., & Strongin, A. Y. (2001). MT1-MMP initiates activation of pro-MMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcinoma cells. Experimental Cell Research, 263(2), 209–223. https://doi.org/10.1006/EXCR.2000.5118.CrossRefPubMed

57.

Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., & Seiki, M. (2001). Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. Journal of Cell Biology, 153(5), 893–904. https://doi.org/10.1083/jcb.153.5.893.CrossRefPubMedPubMedCentral

58.

Symowicz, J., Adley, B. P., Gleason, K. J., Johnson, J. J., Ghosh, S., Fishman, D. A., … Stack, M. S. (2007). Engagement of collagen-binding integrins promotes matrix metalloproteinase-9–dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Research, 67(5), 2030–2039. doi:https://doi.org/10.1158/0008-5472.CAN-06-2808.PubMedCrossRef

59.

Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., & Bissell, M. J. (1997). Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. The Journal of Cell Biology, 139(7), 1861–1872.PubMedPubMedCentralCrossRef

60.

Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., … Saftig, P. (2005). ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proceedings of the National Academy of Sciences of the United States of America, 102(26), 9182–7. doi:https://doi.org/10.1073/pnas.0500918102.CrossRef

61.

Covington, M. D., Burghardt, R. C., & Parrish, A. R. (2006). Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). American Journal of Physiology. Renal Physiology, 290(1), F43–F51. https://doi.org/10.1152/ajprenal.00179.2005.CrossRefPubMed

62.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, 2(3), 161–174. https://doi.org/10.1038/nrc745.CrossRefPubMed

63.

Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., & Baselga, J. (1999). Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Research, 59(6), 1196–1201.PubMed

64.

Vecchi, M., Rudolph-Owen, L. A., Brown, C. L., Dempsey, P. J., & Carpenter, G. (1998). Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. The Journal of Biological Chemistry, 273(32), 20589–20595. https://doi.org/10.1074/JBC.273.32.20589.CrossRefPubMed

65.

Nath, D., Williamson, N. J., Jarvis, R., & Murphy, G. (2001). Shedding of c-met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. Journal of Cell Science, 114(Pt 6), 1213–1220. https://doi.org/10.1242/jcs.152595.CrossRefPubMed

66.

Illman, S. A., Lehti, K., Keski-Oja, J., & Lohi, J. (2006). Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. Journal of Cell Science, 119(Pt 18), 3856–3865. https://doi.org/10.1242/jcs.03157.CrossRefPubMed

67.

Zheng, G., Lyons, J. G., Thian, K. T., Wang, Y., Hsu, T. T., Min, D., … Harris, D. C. H. (2009). Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-β1 in renal tubular epithelial cells. American Journal of Pathology, 175(2), 580–591. doi:https://doi.org/10.2353/ajpath.2009.080983.PubMedPubMedCentralCrossRef

68.

Cheng, S., & Lovett, D. H. (2003). Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. The American Journal of Pathology, 162(6), 1937–1949. https://doi.org/10.1016/S0002-9440(10)64327-1.CrossRefPubMedPubMedCentral

69.

Tan, T. K., Zheng, G., Hsu, T. T., Wang, Y., Lee, V. W. S., Tian, X., … Harris, D. C. H. (2010). Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. American Journal of Pathology, 176(3), 1256–1270. doi:https://doi.org/10.2353/ajpath.2010.090188.PubMedPubMedCentralCrossRef

70.

Cao, J., Chiarelli, C., Richman, O., Zarrabi, K., Kozarekar, P., & Zucker, S. (2008). Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. The Journal of Biological Chemistry, 283(10), 6232–6240. https://doi.org/10.1074/jbc.M705759200.CrossRefPubMed

71.

Sternlicht, M. D., Bissell, M. J., & Werb, Z. (2000). The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene, 19(8), 1102–1113. https://doi.org/10.1038/sj.onc.1203347.CrossRefPubMedPubMedCentral

72.

Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., … Bissell, M. J. (2005). Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature, 436(7047), 123–7. doi:https://doi.org/10.1038/nature03688.PubMedPubMedCentralCrossRef

73.

Chen, Q. K., Lee, K., Radisky, D. C., & Nelson, C. M. (2013). Extracellular matrix proteins regulate epithelial-mesenchymal transition in mammary epithelial cells. Differentiation; Research in Biological Diversity, 86(3), 126–132. https://doi.org/10.1016/j.diff.2013.03.003.CrossRefPubMedPubMedCentral

74.

Lee, K., Chen, Q. K., Lui, C., Cichon, M. A., Radisky, D. C., & Nelson, C. M. (2012). Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Molecular Biology of the Cell, 23(20), 4097–4108. https://doi.org/10.1091/mbc.E12-02-0166.CrossRefPubMedPubMedCentral

75.

Yu, G., Herazo-Maya, J. D., Nukui, T., Romkes, M., Parwani, A., Juan-Guardela, B. M., … Kass, D. J. (2014). Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 190(7), 780–90. doi:https://doi.org/10.1164/rccm.201310-1903OC.PubMedPubMedCentralCrossRef

76.

Pastushenko, I., & Blanpain, C. (2019). EMT transition states during tumor progression and metastasis. Trends in Cell Biology. Elsevier Current Trends. https://doi.org/10.1016/j.tcb.2018.12.001.PubMedCrossRef

77.

Hillebrand, L. E., Wickberg, S. M., Gomez-Auli, A., Follo, M., Maurer, J., Busch, H., … Reinheckel, T. (2018). MMP14 empowers tumor-initiating breast cancer cells under hypoxic nutrient-depleted conditions. The FASEB Journal, 33(3), 4124–4140. doi:https://doi.org/10.1096/fj.201801127r.PubMedCrossRef

78.

Pang, L., Li, Q., Li, S., He, J., Cao, W., Lan, J., … Li, F. (2016). Membrane type 1-matrix metalloproteinase induces epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: observations from clinical and in vitro analyses. Scientific Reports, 6(1), 22179. doi:https://doi.org/10.1038/srep22179.

79.

Yang, C.-C., Zhu, L.-F., Xu, X.-H., Ning, T.-Y., Ye, J.-H., & Liu, L.-K. (2013). Membrane type 1 matrix metalloproteinase induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. BMC Cancer, 13(1), 171. https://doi.org/10.1186/1471-2407-13-171.CrossRefPubMedPubMedCentral

80.

Nguyen, H.-L., Kadam, P., Helkin, A., Cao, K., Wu, S. J., Samara, G., …, Cao, J. (2016). MT1-MMP activation of TGF-? Signaling enables intercellular activation of an epithelial-mesenchymal transition program in cancer. Current Cancer Drug Targets, 16(7), 618–630. doi:https://doi.org/10.2174/1568009616666160216125634.PubMedCrossRef

81.

Qin, G., Luo, M., Chen, J., Dang, Y., Chen, G., Li, L., …, Yang, J. (2016). Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma. Cancer Letters, 374(1), 85–95. doi:https://doi.org/10.1016/j.canlet.2016.02.001.PubMedCrossRef

82.

Bai, X., Li, Y.-Y., Zhang, H.-Y., Wang, F., He, H.-L., Yao, J.-C., …, Li, S.-S. (2017). Role of matrix metalloproteinase-9 in transforming growth factor-β1-induced epithelial-mesenchymal transition in esophageal squamous cell carcinoma. OncologyTargets and Therapy, 10, 2837–2847. doi:https://doi.org/10.2147/OTT.S134813.

83.

Krstic, J., & Santibanez, J. F. (2014). Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. TheScientificWorldJournal, 2014, 521754. https://doi.org/10.1155/2014/521754.CrossRefPubMedPubMedCentral

84.

Santibanez, J. F., Obradović, H., Kukolj, T., & Krstić, J. (2018). Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition. Developmental Dynamics, 247(3), 382–395. https://doi.org/10.1002/dvdy.24554.CrossRefPubMed

85.

Weber, S., & Saftig, P. (2012). Ectodomain shedding and ADAMs in development. Development, 139(20), 3693–3709. https://doi.org/10.1242/DEV.076398.CrossRefPubMed

86.

Murphy, G. (2008). The ADAMs: signalling scissors in the tumour microenvironment. Nature Reviews Cancer, 8(12), 932–941. https://doi.org/10.1038/nrc2459.CrossRef

87.

Becherer, J. D., & Blobel, C. P. (2003). Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Current Topics in Developmental Biology, 54, 101–123. https://doi.org/10.1016/S0070-2153(03)54006-6.CrossRefPubMed

88.

Dong, Y., Wu, Z., He, M., Chen, Y., Chen, Y., Shen, X., … Zeng, Z. (2018). ADAM9 mediates the interleukin-6-induced epithelial–mesenchymal transition and metastasis through ROS production in hepatoma cells. Cancer Letters, 421, 1–14. doi:https://doi.org/10.1016/J.CANLET.2018.02.010.PubMedCrossRef

89.

Pruessmeyer, J., & Ludwig, A. (2009). The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Seminars in Cell & Developmental Biology, 20(2), 164–174. https://doi.org/10.1016/J.SEMCDB.2008.09.005.CrossRef

90.

Atapattu, L., Saha, N., Chheang, C., Eissman, M. F., Xu, K., Vail, M. E., … Janes, P. W. (2016). An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. Journal of Experimental Medicine, 213(9), 1741–1757. doi:https://doi.org/10.1084/JEM.20151095.PubMedPubMedCentralCrossRef

91.

Cai, M., Wang, Z., Zhang, J., Zhou, H., Jin, L., Bai, R., & Weng, Y. (2015). Adam17, a target of Mir-326, promotes Emt-induced cells invasion in lung adenocarcinoma. Cellular Physiology and Biochemistry, 36(3), 1175–1185. https://doi.org/10.1159/000430288.CrossRefPubMed

92.

Ruff, M., Leyme, A., Le Cann, F., Bonnier, D., Le Seyec, J., Chesnel, F., … Théret, N. (2015). The disintegrin and metalloprotease ADAM12 is associated with TGF-β-induced epithelial to mesenchymal transition. PLoS One, 10(9), e0139179. doi:https://doi.org/10.1371/journal.pone.0139179.PubMedPubMedCentralCrossRef

93.

Wang, J., Zhang, Z., Li, R., Mao, F., Sun, W., Chen, J., … Lei, T. (2018). ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomedicine & Pharmacotherapy, 97, 1066–1077. doi:https://doi.org/10.1016/J.BIOPHA.2017.11.034.CrossRef

94.

Najy, A. J., Day, K. C., & Day, M. L. (2008). The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. Journal of Biological Chemistry, 283(26), 18393–18401. https://doi.org/10.1074/JBC.M801329200.CrossRefPubMedPubMedCentral

95.

Bugge, T. H., Antalis, T. M., & Wu, Q. (2009). Type II transmembrane serine proteases. The Journal of Biological Chemistry, 284(35), 23177–23181. https://doi.org/10.1074/jbc.R109.021006.CrossRefPubMedPubMedCentral

96.

Choi, S. Y., Bertram, S., Glowacka, I., Park, Y. W., & Pöhlmann, S. (2009, July 1). Type II transmembrane serine proteases in cancer and viral infections. Trends in Molecular Medicine. Elsevier Current Trends. https://doi.org/10.1016/j.molmed.2009.05.003.PubMedCrossRef

97.

Jung, H., Lee, K. P., Park, S. J., Park, J. H., Jang, Y., Choi, S.-Y., … Park, Y. W. (2008). TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial–mesenchymal transition. Oncogene, 27(18), 2635–2647. doi:https://doi.org/10.1038/sj.onc.1210914.PubMedCrossRef

98.

Wang, C.-H., Guo, Z.-Y., Chen, Z.-T., Zhi, X.-T., Li, D.-K., Dong, Z.-R., … Li, T. (2015). TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection OPEN. doi:https://doi.org/10.1038/srep12366.

99.

Li, S.-L., Chen, X., Wu, T., Zhang, X.-W., Li, H., Zhang, Y., & Ji, Z.-Z. (2018). Knockdown of TMPRSS3 inhibits gastric cancer cell proliferation, invasion and EMT via regulation of the ERK1/2 and PI3K/Akt pathways. Biomedicine & Pharmacotherapy, 107, 841–848. https://doi.org/10.1016/J.BIOPHA.2018.08.023.CrossRef

100.

Lucas, J. M., Heinlein, C., Kim, T., Hernandez, S. A., Malik, M. S., True, L. D., … Nelson, P. S. (2014). The androgen-regulated protease TMPRSS2 activates aProteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discovery, 4(11), 1310. doi:https://doi.org/10.1158/2159-8290.CD-13-1010.PubMedPubMedCentralCrossRef

101.

Pawar, N. R., Buzza, M. S., & Antalis, T. M. (2019). Membrane-anchored serine proteases and protease-activated receptor-2–mediated signaling: co-conspirators in cancer progression. Cancer Research, 79(2), 301–310. https://doi.org/10.1158/0008-5472.CAN-18-1745.CrossRefPubMedPubMedCentral

102.

Lehner, A., Magdolen, V., Schuster, T., Kotzsch, M., Kiechle, M., Meindl, A., … Gross, E. (2013). Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One, 8(4), e60359. doi:https://doi.org/10.1371/journal.pone.0060359.PubMedPubMedCentralCrossRef

103.

Zhu, F., Duan, Y.-F., Bao, W.-Y., Liu, W.-S., Yang, Y., & Cai, H.-H. (2015). HtrA1 regulates epithelial–mesenchymal transition in hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 467(3), 589–594. https://doi.org/10.1016/j.bbrc.2015.09.105.CrossRefPubMed

104.

Wang, N., Eckert, K. A., Zomorrodi, A. R., Xin, P., Pan, W., Shearer, D. A., … Clawson, G. A. (2012). Down-regulation of HtrA1 activates the epithelial-mesenchymal transition and ATM DNA damage response pathways. PLoS One, 7(6), e39446. doi:https://doi.org/10.1371/journal.pone.0039446.PubMedPubMedCentralCrossRef

105.

Glickman, M. H., & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82(2), 373–428. https://doi.org/10.1152/physrev.00027.2001.CrossRefPubMed

106.

Pickart, C. M., & Eddins, M. J. (2004). Ubiquitin: structures, functions, mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1695(1–3), 55–72. https://doi.org/10.1016/J.BBAMCR.2004.09.019.CrossRef

107.

Pfoh, R., Lacdao, I. K., & Saridakis, V. (2015). Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocrine-Related Cancer, 22(1), T35. https://doi.org/10.1530/ERC-14-0516.CrossRefPubMedPubMedCentral

108.

Farshi, P., Deshmukh, R. R., Nwankwo, J. O., Arkwright, R. T., Cvek, B., Liu, J., & Dou, Q. P. (2015). Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 25(10), 1191–1208. https://doi.org/10.1517/13543776.2015.1056737.CrossRefPubMedPubMedCentral

109.

Yuan, T., Yan, F., Ying, M., Cao, J., He, Q., Zhu, H., & Yang, B. (2018). Inhibition of ubiquitin-specific proteases as a novel anticancer therapeutic strategy. Frontiers in Pharmacology, 9, 1080. https://doi.org/10.3389/fphar.2018.01080.CrossRefPubMedPubMedCentral

110.

Choi, B.-J., Park, S.-A., Lee, S.-Y., Cha, Y. N., & Surh, Y.-J. (2017). Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of snail: a potential role of Sox9. Scientific Reports, 7(1), 15918. https://doi.org/10.1038/s41598-017-15139-5.CrossRefPubMedPubMedCentral

111.

Meng, J., Ai, X., Lei, Y., Zhong, W., Qian, B., Qiao, K., … Yang, C. (2019). USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics, 9(2), 573–587. doi:https://doi.org/10.7150/thno.27654.PubMedPubMedCentralCrossRef

112.

Ouchida, A. T., Kacal, M., Zheng, A., Ambroise, G., Zhang, B., Norberg, E., & Vakifahmetoglu-Norberg, H. (2018). USP10 regulates the stability of the EMT-transcription factor slug/SNAI2. Biochemical and Biophysical Research Communications, 502(4), 429–434. https://doi.org/10.1016/J.BBRC.2018.05.156.CrossRefPubMed

113.

Zeng, Q., Li, Z., Zhao, X., Guo, L., Yu, C., Qin, J., … Yang, X. (2018). Ubiquitin-specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial-mesenchymal transition. Oncology Reports, 41(1), 543–551. doi:https://doi.org/10.3892/or.2018.6835.

114.

Liu, S., de Boeck, M., van Dam, H., & ten Dijke, P. (2016). Regulation of the TGF-β pathway by deubiquitinases in cancer. The International Journal of Biochemistry & Cell Biology, 76, 135–145. https://doi.org/10.1016/J.BIOCEL.2016.05.001.CrossRef

115.

Wicks, S. J., Haros, K., Maillard, M., Song, L., Cohen, R. E., ten Dijke, P., & Chantry, A. (2005). The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-β signalling. Oncogene, 24(54), 8080–8084. https://doi.org/10.1038/sj.onc.1208944.CrossRefPubMed

116.

Eichhorn, P. J. A., Rodón, L., Gonzàlez-Juncà, A., Dirac, A., Gili, M., Martínez-Sáez, E., et al. (2012). USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine, 18(3), 429–435. https://doi.org/10.1038/nm.2619.CrossRefPubMed

117.

Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., … ten Dijke, P. (2012). USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nature Cell Biology, 14(7), 717–726. doi:https://doi.org/10.1038/ncb2522.PubMedCrossRef

118.

Wiener, R., Zhang, X., Wang, T., & Wolberger, C. (2012). The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature, 483(7391), 618–622. https://doi.org/10.1038/nature10911.CrossRefPubMedPubMedCentral

119.

Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zacchigna, L., Adorno, M., … Piccolo, S. (2009). FAM/USP9x, a deubiquitinating enzyme essential for TGFβ signaling, controls Smad4 monoubiquitination. Cell, 136(1), 123–135. doi:https://doi.org/10.1016/J.CELL.2008.10.051.PubMedCrossRef

120.

Zhao, Y., Thornton, A. M., Kinney, M. C., Ma, C. A., Spinner, J. J., Fuss, I. J., … Jain, A. (2011). The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells. The Journal of Biological Chemistry, 286(47), 40520. doi:https://doi.org/10.1074/JBC.M111.292961.PubMedCrossRefPubMedCentral

121.

Chanda, A., Sarkar, A., & Bonni, S. (2018). The SUMO system and TGFβ signaling interplay in regulation of epithelial-mesenchymal transition: implications for cancer progression. Cancers, 10(8), E264. https://doi.org/10.3390/cancers10080264.CrossRefPubMed

122.

Chang, C.-C., Huang, Y.-S., Lin, Y.-M., Lin, C.-J., Jeng, J.-C., Liu, S.-M., … Shih, H.-M. (2018). The role of sentrin-specific protease 2 substrate recognition in TGF-β-induced tumorigenesis. Scientific Reports, 8(1), 9786. doi:https://doi.org/10.1038/s41598-018-28103-8.

123.

Chandhoke, A. S., Karve, K., Dadakhujaev, S., Netherton, S., Deng, L., & Bonni, S. (2016). The ubiquitin ligase Smurf2 suppresses TGFβ-induced epithelial–mesenchymal transition in a sumoylation-regulated manner. Cell Death and Differentiation, 23(5), 876. https://doi.org/10.1038/CDD.2015.152.CrossRefPubMed

124.

Stoka, V., Turk, V., & Turk, B. (2016). Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Research Reviews, 32, 22–37. https://doi.org/10.1016/J.ARR.2016.04.010.CrossRefPubMed

125.

Ketterer, S., Gomez-Auli, A., Hillebrand, L. E., Petrera, A., Ketscher, A., & Reinheckel, T. (2017). Inherited diseases caused by mutations in cathepsin protease genes. The FEBS Journal, 284(10), 1437–1454. https://doi.org/10.1111/febs.13980.CrossRefPubMed

126.

van Kasteren, S. I., & Overkleeft, H. S. (2014). Endo-lysosomal proteases in antigen presentation. Current Opinion in Chemical Biology, 23, 8–15. https://doi.org/10.1016/J.CBPA.2014.08.011.CrossRefPubMed

127.

Tan, G.-J., Peng, Z.-K., Lu, J.-P., & Tang, F.-Q. (2013). Cathepsins mediate tumor metastasis. World Journal of Biological Chemistry, 4(4), 91–101. https://doi.org/10.4331/wjbc.v4.i4.91.CrossRefPubMedPubMedCentral

128.

Vizovišek, M., Fonović, M., & Turk, B. (2019). Cysteine cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biology, 75–76, 141–159. https://doi.org/10.1016/J.MATBIO.2018.01.024.CrossRefPubMed

129.

Aits, S., & Jä, M. (n.d.). Lysosomal cell death at a glance. Journal of Cell Science, 126, 1905–1912. https://doi.org/10.1242/jcs.091181.PubMedCrossRef

130.

Campden, R. I., & Zhang, Y. (2019). The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/J.ABB.2019.02.015.PubMedCrossRef

131.

Kern, U., Wischnewski, V., Biniossek, M. L., Schilling, O., & Reinheckel, T. (2015). Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells. Molecular Cancer, 14(1), 39. https://doi.org/10.1186/s12943-015-0313-5.CrossRefPubMedPubMedCentral

132.

Kryczka, J., Papiewska-Pajak, I., Kowalska, M. A., Boncela, J., Kryczka, J., Papiewska-Pajak, I., … Boncela, J. (2019). Cathepsin B is upregulated and mediates ECM degradation in colon adenocarcinoma HT29 cells overexpressing Snail. Cells, 8(3), 203. doi:https://doi.org/10.3390/cells8030203.PubMedCentralCrossRef

133.

Mitrović, A., Pečar Fonović, U., & Kos, J. (2017). Cysteine cathepsins B and X promote epithelial-mesenchymal transition of tumor cells. European Journal of Cell Biology, 96(6), 622–631. https://doi.org/10.1016/J.EJCB.2017.04.003.CrossRefPubMed

134.

Wang, J., Chen, L., Li, Y., & Guan, X.-Y. (2011). Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS One, 6(9), e24967. https://doi.org/10.1371/journal.pone.0024967.CrossRefPubMedPubMedCentral

135.

Burton, L. J., Dougan, J., Jones, J., Smith, B. N., Randle, D., Henderson, V., & Odero-Marah, V. A. (2017). Targeting the nuclear Cathepsin L CCAAT displacement protein/cut Homeobox transcription factor-epithelial mesenchymal transition pathway in prostate and breast cancer cells with the Z-FY-CHO inhibitor. Molecular and Cellular Biology, 37(5), e00297–e00216. https://doi.org/10.1128/MCB.00297-16.CrossRefPubMedPubMedCentral

136.

Kedinger, V., Sansregret, L., Harada, R., Vadnais, C., Cadieux, C., Fathers, K., … Nepveu, A. (2009). p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. The Journal of Biological Chemistry, 284(40), 27701–11. doi:https://doi.org/10.1074/jbc.M109.031849.PubMedCrossRefPubMedCentral

137.

Han, M.-L., Zhao, Y.-F., Tan, C.-H., Xiong, Y.-J., Wang, W.-J., Wu, F., … Liang, Z.-Q. (2016). Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacologica Sinica, 37(12), 1606–1622. doi:https://doi.org/10.1038/aps.2016.93.PubMedPubMedCentralCrossRef

138.

Wang, W., Xiong, Y., Ding, X., Wang, L., Zhao, Y., Fei, Y., … Liang, Z. (2019). Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC. Journal of Experimental & Clinical Cancer Research, 38(1), 61. doi:https://doi.org/10.1186/s13046-019-1054-x.

139.

Zhang, Q., Han, M., Wang, W., Song, Y., Chen, G., Wang, Z., & Liang, Z. (2015). Downregulation of cathepsin L suppresses cancer invasion and migration by inhibiting transforming growth factor-β-mediated epithelial-mesenchymal transition. Oncology Reports, 33(4), 1851–1859. https://doi.org/10.3892/or.2015.3754.CrossRefPubMed

140.

Bonnans, C., Chou, J., & Werb, Z. (2014). Remodelling the extracellular matrix in development and disease. Nature Reviews. Molecular Cell Biology, 15(12), 786–801. https://doi.org/10.1038/nrm3904.CrossRefPubMedPubMedCentral

141.

Conlon, G. A., & Murray, G. I. (2019). Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. The Journal of Pathology, 247(5), 629–640. https://doi.org/10.1002/path.5225.CrossRefPubMed

142.

Overall, C. M., & Dean, R. A. (2006). Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer and Metastasis Reviews, 25(1), 69–75. https://doi.org/10.1007/s10555-006-7890-0.CrossRefPubMed

143.

Lawrence, R. E., & Zoncu, R. (2019). The lysosome as a cellular centre for signalling, metabolism and quality control. Nature Cell Biology, 21(2), 133–142. https://doi.org/10.1038/s41556-018-0244-7.CrossRefPubMed

144.

López-Otín, C., & Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nature Reviews Cancer, 7(10), 800–808. https://doi.org/10.1038/nrc2228.CrossRefPubMed

145.

Dennemärker, J., Lohmüller, T., Mayerle, J., Tacke, M., Lerch, M. M., Coussens, L. M., … Reinheckel, T. (2010). Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene, 29(11), 1611–21. doi:https://doi.org/10.1038/onc.2009.466.PubMedPubMedCentralCrossRef

Titel: The role of proteases in epithelial-to-mesenchymal cell transitions in cancer
verfasst von: Julia Mitschke
Ulrike C. Burk
Thomas Reinheckel
Publikationsdatum: 03.09.2019
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09808-2

Springer Medizin

The role of proteases in epithelial-to-mesenchymal cell transitions in cancer

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Differential roles of protease isoforms in the tumor microenvironment

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

Exosomes as a storehouse of tissue remodeling proteases and mediators of cancer progression

Cell surface–anchored serine proteases in cancer progression and metastasis

Update on gastric cancer treatments and gene therapies

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie